# JOINT Corp: Form 10-Q for the period ended Mar 31, 2024

- Company: [JOINT Corp](/companies/jynt.md) (CIK 1612630)
- Form: 10-Q
- Filed: 2024-05-03
- Accepted by EDGAR: May 2, 2024, 19:05 ET
- Period: 2024-03-31
- Accession: 0001612630-24-000006
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1612630/000161263024000006/jynt-20240331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1612630/000161263024000006/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-01-01 to 2024-03-31 | $29.7m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2024-01-01 to 2024-03-31 | $2.7m | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months, 2024-01-01 to 2024-03-31 | $25.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-01-01 to 2024-03-31 | $1.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2024-01-01 to 2024-03-31 | $178.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-01-01 to 2024-03-31 | $947.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-01-01 to 2024-03-31 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-01-01 to 2024-03-31 | $0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-01-01 to 2024-03-31 | 15,011,286 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2024-01-01 to 2024-03-31 | $2.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2024-01-01 to 2024-03-31 | $395.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months, 2024-01-01 to 2024-03-31 | $6.6k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2024-03-31 | $18.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-03-31 | $44.6m | us-gaap:AssetsCurrent |
| Total assets | at 2024-03-31 | $85.7m | us-gaap:Assets |
| Current liabilities | at 2024-03-31 | $33.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-03-31 | $59.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2024-03-31 | $26.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 35,460 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2023 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K.*

### Forward-Looking Statements

*This Quarterly Report on Form 10-Q, especially in this Management’s Discussion and Analysis or MD&A, contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, included or incorporated in this Form 10-Q could be deemed forward-looking statements, particularly statements about our plans, strategies and prospects under the heading “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “intend,” “seek,” “strive,” or the negative of these terms, “mission,” “goal,” “objective,” or “strategy,” or other comparable terminology. All forward-looking statements in this Form 10-Q are made based on our current expectations, forecasts, estimates and assumptions and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements. In evaluating these statements, you should specifically consider various factors, uncertainties and risks that could affect our future results or operations as described from time to time in our SEC reports, including those risks outlined under “Risk Factors” which are contained in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023 and in Part II, Item 1A of this or any subsequent quarterly reports on Form 10-Q. These factors, uncertainties and risks may cause our actual results to differ materially from any forward-looking statement set forth in this Form 10-Q. You should carefully consider the trends, risks and uncertainties described below and other information contained in the reports we file with or furnish to the SEC before making any investment decision with respect to our securities. We undertake no obligation to update or revise publicly any forward-looking statements, other than in accordance with legal and regulatory obligations. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.*

#### The specific forward-looking statements in this Quarterly Report on Form 10-Q include the following:

- *that we seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry through the rapid and focused expansion of chiropractic clinics in key markets throughout North America and potentially abroad;*
- *our belief that our monthly performance reports from our system and our clinics include key performance indicators per clinic, including gross sales, comparable same-store sales growth, or “Comp Sales,” number of new patients, conversion percentage and membership attrition;*
- *our plan to re-franchise or sell the majority of our company-owned or managed clinics, which refined strategy will leverage our greatest strength - our capacity to build a franchise - to drive long-term growth for both our franchisees and The Joint as a public company;*
- *our belief that the strong results with respect to our franchise licenses sold and our regional developers reflects the power of the regional developer program to accelerate the number of clinics sold, and eventually opened across the country;*
- *our belief that we continue to have a sound business concept and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness;*
- *our belief that these trends join with the preference we have seen among chiropractic doctors to reject the insurance-based model to produce a combination that benefits the consumer and the service provider alike, and our belief that these forces create an important opportunity to accelerate the growth of our network;*
- *our belief that recent events that may impact our business include unfavorable global economic or political conditions, such as the Ukraine War, the Israel-Gaza conflict, labor shortages, and inflation and other cost increases;*
- *our anticipation that 2024 will continue to be a volatile macroeconomic environment;*
- *our belief that we have created a robust framework for the re-franchising effort, organizing clinics into clusters, and generating comprehensive disclosure packets for marketing efficiency, and that we have received significant interest to date from our existing franchisees;*
- *our goal to generate significant processes that will provide us with value creating capital allocation opportunities, which opportunities could include, but are not limited to, reinvestment in the brand and related marketing, continued investment in our IT platforms, the repurchase of RD territories, and/or a stock repurchase program;*
- *our belief that our operating results may fluctuate significantly as a result of a variety of factors, including the timing of new clinic sales, openings, closures, markets in which they are contained and related expenses, general economic conditions, cost inflation, labor shortages, consumer confidence in the economy, consumer preferences, competitive factors, and disease epidemics and other health-related concerns, such as the COVID-19 pandemic;*
- *our belief that our existing cash and cash equivalents, our anticipated cash flows from operations and amounts available under our line of credit will be sufficient to fund our anticipated operating and investment needs for at least the next 12 months;*
- *our belief that we have adequate capital resources and sufficient access to external financing sources to satisfy our current and reasonably anticipated requirements for funds to conduct our operations and meet other needs in the ordinary course of our business; and*
- *our expectation that for the remainder of 2024, we expect to use or redelploy our cash resources to support our business within the context of prevailing market conditions, which, given the ongoing uncertainties described above, could rapidly and materially deteriorate or otherwise change.*

*Some of the important factors that could cause our actual results to differ materially from those projected in any forward-looking statements include, but are not limited to, the following:*

- *the nationwide labor shortage has negatively impacted our ability to recruit chiropractors and other qualified personnel, which may limit our growth strategy, and the measures we have taken in response to the labor shortage have reduced our net revenues;*
- *inflation has led to increased labor costs and interest rates and may lead to reduced discretionary spending, all of which may negatively impact our business;*
- *the COVID-19 pandemic has caused significant disruption to our operations and may continue to impact our business, key financial and operating metrics, and results of operations in numerous ways that remain unpredictable; future widespread outbreaks of contagious disease could similarly disrupt our business;*
- *we may not be able to successfully implement our growth strategy if our franchisees are unable to locate and secure appropriate sites for clinic locations, obtain favorable lease terms, and attract patients to our clinics;*
- *we have limited experience operating company-owned or managed clinics in those geographic areas where we currently have few or no clinics, and we may not be able to duplicate the success of some of our franchisees;*
- *short-selling strategies and negative opinions posted on the internet may drive down the market price of our common stock and could result in class action lawsuits;*
- *we have previously identified material weaknesses in our internal controls over financial reporting and we may fail to remediate future material weaknesses in our internal controls over financial reporting or may otherwise be unable to maintain an effective system of internal control over financial reporting, which might negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence;*
- *we may fail to successfully design and maintain our proprietary and third-party management information systems or implement new systems;*
- *we have restated our prior consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on our stock price;*
- *we may fail to properly maintain the integrity of our data or to strategically implement, upgrade or consolidate existing information systems;*
- *we may not be able to continue to sell franchises to qualified franchisees, and our franchisees may not succeed in developing profitable territories and clinics;*
- *new clinics may not reach the point of profitability, and we may not be able to maintain or improve revenues and franchise fees from existing franchised clinics;*
- *the chiropractic industry is highly competitive, with many well-established independent competitors, which could prevent us from increasing our market share or result in reduction in our market share;*
- *state administrative actions and rulings regarding the corporate practice of chiropractic and prepayment of chiropractic services may jeopardize our business model;*
- *expected new federal regulations and state laws and regulations regarding joint employer responsibility could negatively impact the franchise business model, increasing our potential liability for employment law violations by our franchisees and the likelihood that we may be required to participate in collective bargaining with our franchisees’ employees;*
- *an increased regulatory focus on the establishment of fair franchise practices could increase our risk of liability in disputes with franchisees and the risk of enforcement actions and penalties;*
- *adverse developments affecting institutions, including bank failures, could adversely affect our liquidity and financial performance;*
- *negative publicity or damage to our reputation, which could arise from concerns expressed by opponents of chiropractic and by chiropractors operating under traditional service models, could adversely impact our operations and financial position;*
- *our IT security systems and those of our third-party service providers (as recently experienced by one of our marketing vendors) may be breached, and we may face civil liability and public perception of our security measures could be diminished, either of which would negatively affect our ability to attract and retain patients;*
- *new SEC regulations governing disclosure about risk management, strategy and governance regarding cybersecurity risks and new requirements for reporting of cybersecurity incidents may increase our compliance costs;*
- *legislation, regulations, as well as new medical procedures and techniques, could reduce or eliminate our competitive advantages; and*
- *the delayed filing of one of our quarterly reports has made us currently ineligible to use a registration statement on Form S-3 to register the offer and sale of securities, which could adversely affect our ability to raise future capital or complete acquisitions.*

*Additionally, there may be other risks that are otherwise described from time to time in the reports that we file with the SEC. Any forward-looking statements in this Quarterly Report on Form 10-Q should be considered in light of various important factors, including the risks and uncertainties listed above, as well as others.*

### Overview

Our principal business is to develop, own, operate, support and manage chiropractic clinics through direct ownership, management arrangements, franchising and regional developers throughout the United States.

We seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry through the rapid and focused expansion of chiropractic clinics in key markets throughout North America and potentially abroad.

*Key Performance Measures.* We receive monthly performance reports from our system and our clinics that include key performance indicators per clinic, including gross sales, comparable same-store sales growth, or “Comp Sales,” number of new patients, conversion percentage and membership attrition. In addition, we review monthly reporting related to system-wide sales, clinic openings, clinic license sales, adjusted EBITDA and various earnings metrics in the aggregate and per clinic. We believe these indicators provide us with useful data with which to measure our performance and to measure our franchisees’ and clinics’ performance. Comp Sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed. System-wide sales include sales at all clinics, whether operated by us or by franchisees. While franchised clinic sales are not recorded as revenues by us, management believes the information is important in understanding the overall brand’s financial performance, because these sales are the basis on which we calculate and record royalty fees and are indicative of the financial health of the franchisee base. Adjusted EBITDA consists of net income before interest, income taxes, depreciation and amortization, acquisition related expenses (which includes contract termination costs associated with reacquired regional developer rights), stock-based compensation expense, bargain purchase gain, (gain) loss on disposition or impairment, costs related to restatement filings, restructuring costs and other income related to the ERC. There were no costs related to restatement filings or bargain purchase gain for the three months ended March 31, 2024 and 2023.

*Key Clinic Development Trends.* As of March 31, 2024, we and our franchisees operated or managed 954 clinics, of which 819 were operated or managed by franchisees and 135 were operated as company-owned or managed clinics. Of the 135 company-owned or managed clinics, 65 were constructed and developed by us, and 70 were acquired from franchisees.

Our current strategy is to grow through the sale and development of additional franchises. After evaluating options for improvement, during 2023 the board authorized management to initiate a plan to re-franchise or sell the majority of our company-owned or managed clinics. This refined strategy will leverage our greatest strength - our capacity to build a franchise - to drive long-term growth for both our franchisees and The Joint as a public company. We have created a robust framework for the re-franchising effort, organizing clinics into clusters, and generating comprehensive disclosure packets for marketing efficiency. We have given initial preference to existing franchisees and have received significant interest to date. Our goal will be to generate significant processes that will provide us with value creating capital allocation opportunities. These opportunities could include, but are not limited to, reinvestment in the brand and related marketing, continued investment in our IT platforms, the repurchase of RD territories, and/or a stock repurchase program.

The number of franchise licenses sold for the year ended December 31, 2023 was 55, compared with 75 and 156 licenses for the years ended December 31, 2022 and 2021, respectively. We ended the first three months of 2024 with 17 regional developers who were responsible for 27% of the 15 licenses sold during the period. This strong result reflects the power of the regional developer program to accelerate the number of clinics sold, and eventually opened, across the United States.

We believe that we continue to have a sound business concept and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness. These trends join with the preference we have seen among chiropractic doctors to reject the insurance-based model to produce a combination that benefits the consumer and the service provider alike. We believe that these forces create an important opportunity to accelerate the growth of our network.

### Recent Events

Recent events that may impact our business include unfavorable global economic or political conditions, such as the Ukraine War, the Israel-Gaza conflict, labor shortages, and inflation and other cost increases. We anticipate that 2024 will continue to be a volatile macroeconomic environment.

The primary inflationary factor affecting our operations is labor costs. In 2023 and 2024, clinics owned or managed by us were negatively impacted by labor shortages and wage increases, which increased our general and administrative expenses. Further, should we fail to continue to increase our wages competitively in response to increasing wage rates, the quality of our workforce could decline, causing our patient service to suffer. While we anticipate that these continued headwinds will be partially mitigated by pricing actions, there can be no assurance that we will be able to continue to take such pricing actions. A continued increase in labor costs could have an adverse effect on our operating costs, financial condition and results of operations.

In addition, the increase in interest rates and the expectation that interest rates will continue to remain elevated may adversely affect patients’ financial conditions, resulting in reduced spending on our services. While the impact of these factors continues to remain uncertain, we will continue to evaluate the extent to which these factors will impact our business, financial condition, or results of operations. These and other uncertainties with respect to these recent events could result in changes to our current expectations.

### Other Significant Events and/or Recent Developments

For the three months ended March 31, 2024, compared to the prior year period:

- System-wide comp sales of clinics that have been open for at least 13 full months increased 3%.
- System-wide comp sales for mature clinics open 48 months or more decreased 3%.
- System-wide sales for all clinics open for any amount of time increased 9%.

### Factors Affecting Our Performance

Our operating results may fluctuate significantly as a result of a variety of factors, including the timing of new clinic sales, openings, closures, markets in which they are contained and related expenses, general economic conditions, cost inflation, labor shortages, consumer confidence in the economy, consumer preferences, competitive factors, and disease epidemics and other health-related concerns, such as the COVID-19 pandemic.

### Critical Accounting Estimates

There were no changes in our critical accounting estimates during the three months ended March 31, 2024 from those set forth in “Significant Accounting Policies and Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2023.

### Results of Operations

The following discussion and analysis of our financial results encompasses our consolidated results and results of our two business segments: Corporate Clinics and Franchise Operations.

### Total Revenues — Three Months Ended March 31, 2024 Compared with Three Months Ended March 31, 2023

Components of revenues were as follows:

| Revenues: | Three Months Ended March 31, 2024 | 2023 | Change from Prior Year | Percent Change from Prior Year |
| --- | ---: | ---: | ---: | ---: |
| Revenues from company-owned or managed clinics | $17,537,504 | $17,127,957 | $409,547 | 2.4% |
| Royalty fees | 7,587,547 | 6,866,023 | $721,524 | 10.5% |
| Franchise fees | 655,873 | 754,425 | $(98,552) | (13.1)% |
| Advertising fund revenue | 2,166,473 | 1,952,406 | $214,067 | 11.0% |
| IT related income and software fees | 1,386,776 | 1,210,005 | $176,771 | 14.6% |
| Other revenues | 387,993 | 390,004 | $(2,011) | (0.5)% |
| Total revenues | $29,722,166 | $28,300,820 | $1,421,346 | 5.0% |

#### Consolidated Results

Total revenues increased by $1.4 million, primarily due to the continued expansion and revenue growth of our franchise base and the continued expansion and revenue growth of our company-owned or managed clinics portfolio.

#### Corporate Clinics

Revenues from company-owned or managed clinics increased, primarily due to the expansion of our company-owned or managed clinics portfolio. As of March 31, 2024 and 2023, there were 135 and 130 company-owned or managed clinics in operation, respectively.

#### Franchise Operations

For the three months ended March 31, 2024, compared to the prior year period:

- Royalty fees and advertising fund revenue increased due to an increase in the number of franchised clinics in operation during the current period, along with continued sales growth in existing franchised clinics. As of March 31, 2024 and 2023, there were 819 and 740 franchised clinics in operation, respectively.
- Franchise fees decreased due to the impact of accelerated revenue recognition resulting from the terminated franchise license agreements during the first quarter of 2023. There were no such comparable events during the first quarter of 2024.
- Software fees revenue increased due to an increase in our franchised clinic base and the related revenue recognition over the term of the franchise agreement, as described in “Revenue Recognition” in Note 1, *Nature of Operations and Summary of Significant Accounting Policies*, to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
- Other revenues primarily consist of merchant income associated with credit card transactions.

| Three Months Ended March 31, | 2024 | 2023 | Change from Prior Year | Percent Change from Prior Year |
| --- | ---: | ---: | ---: | ---: |
| Cost of Revenues | $2,716,076 | $2,474,685 | $241,391 | 9.8% |

For the three months ended March 31, 2024, as compared with the three months ended March 31, 2023, the total cost of revenues increased primarily due to an increase in regional developer royalties of $0.2 million.

### Selling and Marketing Expenses

| Three Months Ended March 31, | 2024 | 2023 | Change from Prior Year | Percent Change from Prior Year |
| --- | ---: | ---: | ---: | ---: |
| Selling and Marketing Expenses | $3,886,113 | $4,160,244 | $(274,131) | (6.6)% |

Selling and marketing expenses decreased for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, driven by: (i) a decrease in local marketing expenditures by the company-owned or managed clinics and (ii) the timing of the national marketing fund spend.

### Depreciation and Amortization Expenses

| Three Months Ended March 31, | 2024 | 2023 | Change from Prior Year | Percent Change from Prior Year |
| --- | ---: | ---: | ---: | ---: |
| Depreciation and Amortization Expenses | $1,403,906 | $2,215,055 | $(811,149) | (36.6)% |

Depreciation and amortization expenses decreased for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, primarily due to no depreciation and amortization expense recorded during the three months ended March 31, 2024 related to the assets held for sale at March 31, 2024.

### General and Administrative Expenses

| Three Months Ended March 31, | 2024 | 2023 | Change from Prior Year | Percent Change from Prior Year |
| --- | ---: | ---: | ---: | ---: |
| General and Administrative Expenses | $20,263,692 | $20,038,476 | $225,216 | 1.1% |

General and administrative expenses increased during the three months ended March 31, 2024 compared to the three months ended March 31, 2023, primarily due to restructuring costs of $0.2 million and due to the increases in the following to support continued clinic count and revenue growth in both operating segments: (i) payroll and related expenses of $0.5 million; and (ii) professional and advisory fees of $0.5 million primarily related to increased audit fees. The increases were partially offset by a decrease of $1.0 million in amortization of ROU assets for the clinics held for sale during the three months ended March 31, 2024.

As a percentage of revenue, general and administrative expenses during the three months ended March 31, 2024 and 2023 were 68% and 71%, respectively.

### Income (Loss) from Operations

| Three Months Ended March 31, | 2024 | 2023 | Change from Prior Year | Percent Change from Prior Year |
| --- | ---: | ---: | ---: | ---: |
| Income (Loss) from Operations | $1,090,276 | $(653,109) | $1,743,385 | (266.9)% |

#### Consolidated Results

Consolidated income from operations increased by $1.7 million for the three months ended March 31, 2024 compared to the three months ended March 31, 2023, primarily due to the discontinued recording of depreciation on property and equipment, net, amortization of intangible assets, net and amortization of ROU assets for the clinics held for sale during the three months ended March 31, 2024, as required by GAAP.

#### Corporate Clinics

Our corporate clinics segment had income from operations of $1.5 million for the three months ended March 31, 2024, an increase of $1.9 million compared to loss from operations of $0.4 million for the prior year period. This increase was primarily due to:

- an increase in revenues of $0.4 million from company-owned or managed clinics; and
- a decrease of $1.8 million in operating expenses due to discontinued recording of depreciation on property and equipment, net, amortization of intangible assets, net and amortization of ROU assets for the clinics held for sale during the three months ended March 31, 2024; partially offset by
- an increase in impairment loss of $0.3 million.

#### Franchise Operations

Our franchise operations segment had income from operations of $5.3 million for the three months ended March 31, 2024, an increase of $0.8 million compared to income from operations of $4.5 million for the prior year period. This increase was primarily due to:

- an increase of $1.0 million in total revenues; partially offset by
- an increase of $0.2 million in cost of revenues primarily due to an increase in regional developer royalties.

#### Unallocated Corporate

Unallocated corporate expenses for the three months ended March 31, 2024 increased by $1.0 million compared to the prior year period, primarily due to the increases in payroll-related expenses due to a higher head count to support the expansion of both operating segments and increases in audit and accounting fees to support the Company as a publicly traded company.

### Other Income, Net

| Three Months Ended March 31, | 2024 | 2023 | Change from Prior Year | Percent Change from Prior Year |
| --- | ---: | ---: | ---: | ---: |
| Other income, net | $35,630 | $3,821,162 | $(3,785,532) | 99.1% |

Other income, net decreased during the three months ended March 31, 2024 compared to the three months ended March 31, 2023, primarily due to the recognition and receipt of the $3.8 million employee retention credits, net of the consulting fee, in the first quarter of 2023. There were no such comparable events during the first quarter of 2024.

### Income Tax Expense

| Three Months Ended March 31, | 2024 | 2023 | Change from Prior Year | Percent Change from Prior Year |
| --- | ---: | ---: | ---: | ---: |
| Income tax expense | $178,927 | $841,889 | $(662,962) | 78.7% |

Income tax expense decreased during the three months ended March 31, 2024 compared to the three months ended March 31, 2023, primarily due to decreased earnings before income tax expense and a change in the valuation allowance assessment as of December 31, 2023, at the Joint Corp.

### Non-GAAP Financial Measures

The following table reconciles net income to Adjusted EBITDA for the three months ended March 31, 2024 and 2023:

| Non-GAAP Financial Data: | Three Months Ended March 31, 2024 | 2023 |
| --- | ---: | ---: |
| Net income | $946,979 | $2,326,164 |
| Net interest expense | (35,630) | 49,725 |
| Depreciation and amortization expense | 1,403,906 | 2,215,055 |
| Tax expense | 178,927 | 841,889 |
| EBITDA | 2,494,182 | 5,432,833 |
| Stock compensation expense | 493,395 | 266,210 |
| Acquisition related expenses | — | 141,693 |
| Loss on disposition or impairment | 362,103 | 65,469 |
| Restructuring costs | 157,035 | — |
| Other (income), net | — | (3,870,887) |
| Adjusted EBITDA | $3,506,715 | $2,035,318 |

Adjusted EBITDA consists of net income before interest, income taxes, depreciation and amortization, acquisition related expenses (which includes contract termination costs associated with reacquired regional developer rights), stock-based compensation expense, bargain purchase gain, (gain) loss on disposition or impairment, costs related to restatement filings, restructuring costs, and other income related to the ERC. There were no costs related to restatement filings or bargain purchase gain for the three months ended March 31, 2024 and 2023. We have provided Adjusted EBITDA because it is a non-GAAP measure of financial performance commonly used for comparing companies in our industry. You should not consider Adjusted EBITDA as a substitute for operating profit as an indicator of our operating performance or as an alternative to cash flows from operating activities as a measure of liquidity. We may calculate Adjusted EBITDA differently from other companies.

We believe that the use of Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with other outpatient medical clinics, which may present similar non-GAAP financial measures to investors. In addition, you should be aware when evaluating Adjusted EBITDA that in the future we may incur expenses similar to those excluded when calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our computation of Adjusted EBITDA may not be comparable to other similarly titled measures computed by other companies, because all companies do not calculate Adjusted EBITDA in the same manner.

### Liquidity and Capital Resources

As of March 31, 2024, we had unrestricted cash and short-term bank deposits of $18.7 million and $20 million of available capacity under the line of credit. While unfavorable global economic or political conditions create potential liquidity risks, as discussed further below, we believe that our existing cash and cash equivalents, our anticipated cash flows from operations, our anticipated cash flows from investments as we execute our re-franchising strategy and amounts available under our line of credit will be sufficient to fund our anticipated operating and investment needs for at least the next 12 months.

While the interruptions, delays and/or cost increases resulting from political instability and geopolitical tensions, economic weakness, inflationary pressures, increase in interest rates and other factors have created uncertainty as to general economic conditions for 2024 and beyond, as of the date of this Quarterly Report on Form 10-Q, we believe we have adequate capital resources and sufficient access to external financing sources to satisfy our current and reasonably anticipated requirements for funds to conduct our operations and meet other needs in the ordinary course of our business. For the remainder of 2024, we expect to use or redeploy our cash resources to support our business within the context of prevailing market conditions, which, given the ongoing uncertainties described above, could rapidly and materially deteriorate or otherwise change. Our long-term capital requirements could be dependent on our ability to access additional funds through the debt and/or equity markets. If the equity or debt markets deteriorate, including as a result of economic weakness, political unrest or war, or any other reason, it may make any necessary equity or debt financing more difficult to obtain in a timely manner and on favorable terms, if at all, and if obtained, it may be more costly or more dilutive. From time to time, we consider and evaluate transactions related to our portfolio and capital structure, including debt financings, equity issuances, purchases and sales of assets, and other transactions. There can be no assurance that we will be able to generate sufficient cash flows or obtain the capital necessary to meet our short and long-term capital requirements.

### Analysis of Cash Flows

Net cash provided by operating activities decreased by $3.2 million to $2.8 million for the three months ended March 31, 2024, compared to $6.0 million for the three months ended March 31, 2023. The decrease was primarily attributable to recognizing the $3.9 million ERC during the Three months ended March 31, 2023, which was partially offset by an increase in revenue over the prior year period, and a decrease in depreciation and amortization expenses over the prior year period.

Net cash used in investing activities was $0.3 million and $1.2 million for the three months ended March 31, 2024 and 2023, respectively. For the three months ended March 31, 2024, this included purchases of property and equipment of $0.4 million. For the three months ended March 31, 2023, this included purchases of property and equipment of $1.2 million.

Net cash used in financing activities for the three months ended March 31, 2024 was $2.0 million, compared to net cash provided by financing activities of $0.1 million for the three months ended March 31, 2023. For the three months ended March 31, 2024, this included paying down the outstanding balance on its Debt under the Credit Agreement of $2.0 million.

### Recent Accounting Pronouncements

See Note 1, *Nature of Operations and Summary of Significant Accounting Policies,* to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for information regarding recently issued accounting pronouncements that may impact our financial statements.

### Off-Balance Sheet Arrangements

During the three months ended March 31, 2024, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements.

## Market risk

As filed, 288 characters.

As of March 31, 2024 there have been no material changes to the quantitative and qualitative disclosures about market risk appearing in Part II, Item 7(a), “Quantitative and Qualitative Disclosures About Market Risk” of our Annual Report on Form 10-K for the year ended December 31, 2023.

## Controls and procedures

As filed, 1,845 characters.

### Evaluation of Disclosure Controls and Procedures

Our management evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures were designed to provide reasonable assurance of achieving such objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2024, our management concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 232 characters.

We documented our risk factors in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to our risk factors since the filing of that Annual Report on Form 10-K.

Filed May 3, 2024.
Source: SEC EDGAR, the filing index for accession 0001612630-24-000006. Last ingested by Listed: Nov 15, 2026, 00:52 ET. No prices; not investment advice.
